|
Age (median, IQR)—yr
|
64 (55–76)
|
66 (56–84)
|
0.494
|
|
Male sex—no. (%)
|
24 (60)
|
19 (48)
|
0.444
|
|
Time from onset of symptoms to DE-CTPA, days (median, IQR)
|
14 (7–18)
|
10 (7–14.5)
|
0.130
|
|
Time from admission to DE-CTPA, days (median, IQR)
|
1 (0–7)
|
0 (0–2)
|
0.045
|
|
Disease extent assessed on CT lung images
|
|
< 10%—no. (%) (limited extent)
|
1 (3)
|
3 (11)
|
0.295
|
|
10–50%—no. (%) (regrouping mild and moderate extent)
|
17 (43)
|
13 (48)
|
0.799
|
|
> 50%—no. (%) (regrouping severe and diffuse extent)
|
22 (55)
|
11 (41)
|
0.321
|
|
Anticoagulant treatment prior to DE-CTPA
|
|
Preventive dosage—no. (%)
|
13 (33)
|
8 (30)
|
1
|
|
Curative dosage—no. (%)
|
5 (13)
|
2 (7)
|
0.693
|
|
Oxygen-support at DE-CTPA
|
|
Invasive ventilation- no. (%)
|
0 (0)
|
1 (4)
|
0.023
|
|
High-flow oxygen (≥ 6 l/min)—no. (%)
|
14 (35)
|
7 (26)
|
0.592
|
|
Low-flow oxygen (< 6 l/min and room air)—no. (%)
|
26 (65)
|
19 (70)
|
0.792
|
|
Highest oxygen-support during hospital stay
|
|
Invasive ventilation- no. (%)
|
9 (23)
|
3 (11)
|
0.335
|
|
High-flow oxygen (≥ 6 l/min)—no. (%)
|
14 (35)
|
9 (33)
|
1
|
|
Low-flow oxygen (< 6 l/min and room air)—no. (%)
|
17 (43)
|
15 (56)
|
0.328
|
|
Biological characteristics
|
|
D-Dimer level just prior to CTPA—median (IQR) ng/mL
|
1340 (910–2625)
|
1590 (1140–2142)
|
0.340
|
|
Highest level of D-dimer during hospitalization – median (IQR) mg/L
|
1760 (1173–4085)
|
2221 (1445–3433)
|
0.305
|
|
Highest level of CRP during hospitalization – median (IQR) mg/L
|
146 (75–194)
|
135 (62–206)
|
0.944
|
|
Prognosis
|
|
Duration of hospital admission (alive patients)- days (median, IQR)
|
14 (8–23)
|
9 (4–17)
|
0.117
|
|
Deaths—no. (%)
|
3 (8)
|
6 (22)
|
0.142
|
